SESSION IV: CHRONIC MYELOID LEUKEMIA

Session Chair: Hagop Kantarjian and Jeffrey Lipton

Choosing the Best First Line Drug – Does Efficacy Make You Think About Cost | Elias Jabbour, MD | MD Anderson Cancer Center, Houston, Texas, USA

Is the Product Monograph Dose of TKI Really What Is Necessary | Jorge E Cortés, MD | Georgia Cancer Center, Augusta, Georgia, USA

Looking for Mutations in CML – When and How? Does Greater Sensitivity Make a Difference or Is It Even Necessary? | Simona Soverini, PhD | University of Bologna, Bologna, Italy

Remembering to Monitor for the Long-Term Side Effects of TKI Therapy: How and for What? | Jeffrey H Lipton, MD, PhD, FRCPC | University of Toronto, Toronto, Canada

I Forgot About Allografting for CML – When Should I Remember? | Jerald P Radich, MD | Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Oral Abstract | CML-387: ASC4FIRST, a Pivotal Phase 3 Study of Asciminib (ASC) vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Patients With Chronic Myeloid Leukemia (CML): Primary Results | Jorge E Cortés, MD | Georgia Cancer Center, Augusta, Georgia, USA